Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
47.64B | 48.30B | 45.01B | 46.16B | 46.38B | 42.52B | Gross Profit |
31.43B | 34.33B | 34.31B | 36.02B | 36.45B | 30.75B | EBIT |
8.79B | 5.89B | 17.24B | 10.33B | 10.16B | 5.13B | EBITDA |
16.18B | 3.22B | 19.42B | 19.23B | 20.19B | 5.04B | Net Income Common Stockholders |
5.42B | -8.95B | 8.03B | 6.33B | 6.99B | -8.99B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
11.78B | 10.86B | 12.28B | 9.12B | 13.98B | 14.55B | Total Assets |
92.43B | 92.60B | 95.16B | 96.82B | 109.31B | 118.48B | Total Debt |
51.24B | 51.20B | 41.46B | 40.72B | 45.60B | 51.67B | Net Debt |
40.36B | 40.85B | 30.00B | 31.59B | 31.62B | 37.13B | Total Liabilities |
74.98B | 76.22B | 65.67B | 65.70B | 73.31B | 80.60B | Stockholders Equity |
17.39B | 16.34B | 29.43B | 31.06B | 35.95B | 37.82B |
Cash Flow | Free Cash Flow | ||||
13.09B | 13.94B | 12.65B | 11.95B | 15.23B | 13.30B | Operating Cash Flow |
14.31B | 15.19B | 13.86B | 13.07B | 16.21B | 14.05B | Investing Cash Flow |
-2.23B | -21.35B | -2.29B | -1.06B | -538.00M | -10.86B | Financing Cash Flow |
-10.51B | 5.13B | -9.42B | -16.96B | -16.22B | -1.15B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $193.93B | 11.24 | 39.31% | 4.09% | 4.40% | 654.93% | |
71 Outperform | $132.06B | 22.32 | 32.51% | 2.92% | 4.63% | 1144.01% | |
71 Outperform | $127.12B | 21.76 | 7.34% | 2.79% | -4.57% | 2.96% | |
66 Neutral | $130.76B | 16.67 | 8.62% | 7.18% | 13.38% | ― | |
63 Neutral | $96.10B | 17.73 | 31.99% | 5.17% | 4.62% | ― | |
63 Neutral | $75.63B | 19.47 | 22.26% | 3.99% | 4.17% | -29.96% | |
52 Neutral | $5.19B | 3.04 | -44.20% | 2.82% | 16.59% | -0.39% |
On May 6, 2025, Bristol-Myers Squibb held its Annual Meeting, where shareholders elected 11 directors to serve until the 2026 meeting. Key decisions included the approval of executive compensation and the ratification of Deloitte & Touche LLP as the independent accounting firm for 2025. However, shareholder proposals on Corporate Financial Sustainability and ceasing DEI efforts were not approved.
Spark’s Take on BMY Stock
According to Spark, TipRanks’ AI Analyst, BMY is a Neutral.
Bristol-Myers Squibb’s overall stock score reflects strong financial performance, particularly in cash flow generation and gross profitability. The recent earnings call provided positive revenue and EPS guidance, supporting a strong outlook. However, technical indicators show bearish momentum, and some regulatory and trial challenges persist. The balanced valuation and attractive dividend yield provide additional support.
To see Spark’s full report on BMY stock, click here.
On April 24, 2025, Bristol Myers Squibb announced its financial results for the first quarter of 2025, reporting total revenues of $11.2 billion, a decrease of 6% compared to the previous year. Despite the decline in total revenues, the company’s Growth Portfolio showed significant progress with a 16% increase in revenues, driven by strong performances from products like Opdivo, Breyanzi, Reblozyl, and Camzyos. The company raised its 2025 revenue guidance to a range of $45.8 billion to $46.8 billion, reflecting confidence in its strategic initiatives and pipeline progress.
Spark’s Take on BMY Stock
According to Spark, TipRanks’ AI Analyst, BMY is a Neutral.
Bristol-Myers Squibb’s overall score reflects strong financial performance in terms of revenue growth and cash flow, but is negatively impacted by significant net losses and high leverage. Technical indicators suggest a bearish trend, while the valuation is pressured by a negative P/E ratio despite a strong dividend yield. The positive sentiment from the earnings call, with optimistic guidance and strategic initiatives, helps counterbalance some risks.
To see Spark’s full report on BMY stock, click here.